StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ENVB yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $2.20 | $2.15 | -2.27% | 0.1M |
| 05-19 | $1.99 | $2.11 | +6.03% | 0.9M |
| 05-20 | $2.06 | $2.20 | +6.80% | 0.1M |
| 05-21 | $2.16 | $2.22 | +2.78% | 0.1M |
| 05-22 | $2.22 | $2.21 | -0.45% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2020 2020-09-30 | Q2 2020 2020-06-30 | Annual 2019 2019-12-31 | Q3 2019 2019-09-30 |
|---|---|---|---|---|
Revenue | $26.34M | $17.86M | $39.91M | $30.85M |
Operating Income | $-2.09M | $-1.60M | $-2.30M | $-4.34M |
Net Income | $-2.48M | $-818.39K | $-2.41M | $-3.08M |
EPS (Diluted) | $-1.11 | $-1.03 | $-2.83 | $-1.70 |
Total Assets | $27.99M | $27.51M | $108.79K | $29.79M |
Total Liabilities | $14.82M | $14.63M | $1.92M | $18.93M |
Cash & Equivalents | $2.84M | $2.09M | $431.40K | $499.69K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 5.74M | 5.16M | 5.31M | 62.82M |
ENVB is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.